ReviewJournal of cellular and molecular medicine2009
Drug releasing systems in cardiovascular tissue engineering.
Review in Journal of cellular and molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Radiolabeled Risperidone microSPECT/CT Imaging for Intranasal Implant Studies Development.Pharmaceutics · 2023Article
- Review of Polymeric Biomimetic Small-Diameter Vascular Grafts to Tackle Intimal Hyperplasia.ACS omega · 2022Review
- LRG-1 promotes fat graft survival through the RAB31-mediated inhibition of hypoxia-induced apoptosis.Journal of cellular and molecular medicine · 2022Article
- Use of 3D Printing for the Development of Biodegradable Antiplatelet Materials for Cardiovascular Applications.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Human cardiac extracellular matrix-chitosan-gelatin composite scaffold and its endothelialization.Experimental and therapeutic medicine · 2020Article
- Marrow-isolated adult multilineage inducible cells embedded within a biologically-inspired construct promote recovery in a mouse model of peripheral vascular disease.Biomedical materials (Bristol, England) · 2017Article
- Implantation of a Poly-L-Lactide GCSF-Functionalized Scaffold in a Model of Chronic Myocardial Infarction.Journal of cardiovascular translational research · 2017Article
- Old Myths, New Concerns: the Long-Term Effects of Ascending Aorta Replacement with Dacron Grafts. Not All That Glitters Is Gold.Journal of cardiovascular translational research · 2016Review
- Preliminary In Vivo Evaluation of a Hybrid Armored Vascular Graft Combining Electrospinning and Additive Manufacturing Techniques.Drug target insights · 2016Article
- CURRENT DEVELOPMENTS IN DRUG ELUTING DEVICES: Introductory Editorial: Drug-Eluting Stents or Drug-Eluting Grafts? Insights from Proteomic Analysis.Drug target insights · 2016Article
- Fabrication of small-diameter vascular scaffolds by heparin-bonded P(LLA-CL) composite nanofibers to improve graft patency.International journal of nanomedicine · 2013Article
- Multifunctional nanoscale strategies for enhancing and monitoring blood vessel regeneration.Nano today · 2012Article
- Biomaterial applications in cardiovascular tissue repair and regeneration.Expert review of cardiovascular therapy · 2012Review
- Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodelling and function of myocardial infarction.Journal of cellular and molecular medicine · 2012Article
- bFGF-containing electrospun gelatin scaffolds with controlled nano-architectural features for directed angiogenesis.Acta biomaterialia · 2012Article
- Strategies for tissue engineering cardiac constructs to affect functional repair following myocardial infarction.Journal of cardiovascular translational research · 2011Review
- Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model.Gene therapy · 2011Article
- A G-CSF functionalized scaffold for stem cells seeding: a differentiating device for cardiac purposes.Journal of cellular and molecular medicine · 2011Article
- Site-specific gene therapy for cardiovascular disease.Current opinion in drug discovery & development · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart disease and atherosclerosis are the leading causes of morbidity and mortality worldwide. The lack of suitable autologous grafts has produced a need for artificial grafts; however, current artificial grafts carry significant limitations, including thrombosis, infection, limited durability and the inability to grow. Tissue engineering of blood vessels, cardiovascular structures and whole organs is a promising approach for creating replacement tissues to repair congenital defects and/or diseased tissues. In an attempt to surmount the shortcomings of artificial grafts, tissue-engineered cardiovascular graft (TECVG), constructs obtained using cultured autologous vascular cells seeded onto a synthetic biodegradable polymer scaffold, have been developed. Autologous TECVGs have the potential advantages of growth, durability, resistance to infection, and freedom from problems of rejection, thrombogenicity and donor scarcity. Moreover polymers engrafted with growth factors, cytokines, drugs have been developed allowing drug-releasing systems capable of focused and localized delivery of molecules depending on the environmental requirements and the milieu in which the scaffold is placed. A broad range of applications for compound-releasing, tissue-engineered grafts have been suggested ranging from drug delivery to gene therapy. This review will describe advances in the development of drug-delivery systems for cardiovascular applications focusing on the manufacturing techniques and on the compounds delivered by these systems to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.